Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shenzhen Salubris Pharmaceuticals Co., Ltd.
  6. News
  7. Summary
    002294   CNE100000FW8

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

(002294)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE : 002294) intends to launch an Equity Buyback Plan.

07/25/2021 | 12:00am EST

On July 25, 2021, Shenzhen Salubris Pharmaceuticals Co., Ltd. announced that it plans start a share buyback program. Under the program, the company will repurchase up to CNY 200 million worth of its shares. The program will be valid for a period of 12 months.


ę S&P Capital IQ 2021
All news about SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
10/25Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Month..
CI
10/07Tranche Update on Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Equity Buyback Plan ann..
CI
09/05Shenzhen Salubris Pharmaceuticals Co., Ltd. announces an Increase in Equity Buyback.
CI
08/23Viracta Up 5% After It Reacquires Rights to Combination Therapy in China
DJ
08/23VIRACTA THERAPEUTICS : Reacquires Exclusive Rights to Combination Therapy Candidate for Ly..
MT
08/23Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year ..
CI
08/06SKILLFUL CRAFTSMAN EDUCATION TECHNOL : Names Dawei Chen as Chief Financial Officer
MT
07/25Shenzhen Salubris Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 200 mil..
CI
07/25Shenzhen Salubris Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.
CI
07/25SHENZHEN SALUBRIS PHARMACEUTICALS CO : 002294) intends to launch an Equity Buyback Plan.
CI
More news
Financials
Sales 2021 3 021 M 475 M 475 M
Net income 2021 619 M 97,3 M 97,3 M
Net cash 2021 301 M 47,3 M 47,3 M
P/E ratio 2021 47,9x
Yield 2021 0,91%
Capitalization 30 540 M 4 796 M 4 798 M
EV / Sales 2021 10,0x
EV / Sales 2022 8,44x
Nbr of Employees 3 448
Free-Float 35,3%
Chart SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Duration : Period :
Shenzhen Salubris Pharmaceuticals Co., Ltd. Technical Analysis Chart | 002294 | CNE100000FW8 | MarketScreener
Technical analysis trends SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 27,61 CNY
Average target price 28,00 CNY
Spread / Average Target 1,41%
EPS Revisions
Managers and Directors
Sing Ye General Manager & Director
Jun Liu Chief Financial Officer
Cheng Hai Ye Chairman
Ai Zhen Li Chairman-Supervisory Board
Ji Tang Member-Supervisory Board & Administrative Director